ArticleAmerican journal of translational research2015
MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- The expression profile and clinical relevance of miR-125a-5p in individuals with chronic periodontitis.Acta odontologica Scandinavica · 2026Article
- The Epigenetic Angle in the Precision Medicine Era for Blood Disorder Advancements.Sub-cellular biochemistry · 2026Review
- The function of T cells in immune thrombocytopenia.Frontiers in immunology · 2025Review
- Pathogenesis of refractory ITP: Overview.British journal of haematology · 2023Review
- Long non-coding RNA maternally expressed gene 3, miR-125a-5p, CXCL13, and NF-kB in patients with immune thrombocytopenia.Genes and immunity · 2023Article
- Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia.International journal of molecular sciences · 2023Review
- A polygenic stacking classifier revealed the complicated platelet transcriptomic landscape of adult immune thrombocytopenia.Molecular therapy. Nucleic acids · 2022Article
- Regulation of mRNA stability by RBPs and noncoding RNAs contributing to the pathogenicity of Th17 cells.RNA biology · 2021Review
- Circulating mRNA and microRNA profiling analysis in patients with ischemic stroke.Molecular medicine reports · 2020Article
- MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018Review
- MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer.Oncology letters · 2017Article
- T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART.Scientific reports · 2017Article
- The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune thrombocytopenia (ITP) is an acquired and autoimmune disease of adults and children characterized by decreased platelet production. CXC chemokine ligand-13 (CXCL13) participates in multiple immunological responses. However, it is still unknown the relationship between CXCL13 and ITP.
methodsPlasma CXCL13 was detected in ITP (n = 30) children. CD4+ T cells was isolated from peripheral blood mononuclear cells (PBMCs) from healthy volunteers. Treated CD4+ T cells with dexamethasone and/or miR-125-5p mimic/inhibitor, to observe the regulation of CXCL13.
resultsCompared with controls, ITP children had elevated plasma CXCL13, the concentration of which was reduced after treatment. In vitro, dexamethasone decreased CXCL13 level in in dose- dependent and in time-dependent manner. MiR-125-5p mimic decreased CXCL13 level and miR-125-5p inhibitor increased CXCL13 level in CD4+ T cells. CXCL13 was implied to be target gene of miR-125-5p. MiR-125-5p inhibitor also canceled dexamethasone induced decrease of CXCL13.
conclusionCXCL13 is the target gene of miR-125-5p, which is possibly involved in the pathological process of ITP.
Indexed as
Identifiers
26064444PMC4455351W2394774663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.